XML 99 R61.htm IDEA: XBRL DOCUMENT v3.25.0.1
Significant agreements - Novartis Collaboration Agreement (Details)
$ in Thousands
 12 Months Ended
Mar. 27, 2023
USD ($)
item
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Significant agreements.        
Maximum days allowed for cancellation of contracts prior written notice   90 days    
Revenue from collaborative arrangement   $ 35,275 $ 26,976 $ 14,463
Deferred revenue   101,658 135,194 61,873
Termination in entirety or product by product or target by target basis        
Significant agreements.        
Threshold period of notice required for termination of agreement 90 days      
Completion of all milestones for targets        
Significant agreements.        
Milestone payments receivable $ 800,000      
Novartis        
Significant agreements.        
Number of collaboration targets | item 2      
Additional research term 1 year      
Upfront cash payment $ 50,000      
Milestone payments receivable 210,000      
Milestone payments, receivable $ 840,000      
Maximum days allowed for cancellation of contracts prior written notice 30 days      
Expected period for satisfaction of performance obligations 3 years      
Material rights exercise period 6 years      
Revenue from collaborative arrangement   8,161 1,909 $ 0
Deferred revenue   44,073 $ 50,008  
Novartis | Termination based on other party's uncured material breach or insolvency        
Significant agreements.        
Threshold period of notice required for termination of agreement 60 days      
Novartis | Termination if safety or regulatory issue exists        
Significant agreements.        
Threshold period of notice required for termination of agreement 30 days      
Novartis | Expiration of two material rights associated with limited substitution rights        
Significant agreements.        
Revenue from collaborative arrangement   $ 2,500    
Novartis | Achievement of specified levels of net sales        
Significant agreements.        
Milestone payments receivable $ 200,000